Accessibility Menu
 

Why Achillion Pharmaceuticals Shares Soared in October

An upcoming trial by Johnson & Johnson that includes a key drug from this tiny drugmaker could eventually reward investors.

By Todd Campbell Updated Nov 7, 2015 at 9:03AM EST

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.